RFA-CK-23-001, Clinical and Applied Research Strategies for the Prevention and Control of Fungal Diseases

项目概要： 这项题为“定义流行病学、诊断、预防和治疗”的提案 在美国的侵袭性真菌感染”是一个雄心勃勃的总体建议， 其涵盖了临床真菌学竞技场中的许多问题。该提案代表了一系列 独立的项目，将在整个过程中顺序启动5- 年奖。真菌病研究小组（MSG）及其中心单位位于UAB， 传染病科将负责管理这一方案。该提案有三大 针对当前一些最重要的公共卫生问题的具体目标， 挑战，因为它涉及真菌感染。在第一个目标中，我们将发展和维护 可靠和创新的国家真菌监测方法，同时评估特定风险 在治疗中获得这些感染的因素以及与这些感染相关的结果 紊乱第二个目标将解决侵袭性真菌病管理方面的巨大差距， 特别是提高真菌诊断的实用性和范围。我们将探讨这一点 通过回顾现有的真菌诊断方法， 与特定患者相关联的存储库，目的是开发新的诊断方法。 最后，我们将探讨具体的公共卫生干预措施，可能有助于减轻 真菌感染在一般人群和特定高危人群中的显著影响 分组。要实现这些宏伟目标，显然需要大力协调 在广泛的研究人员，临床中心，实验室和CDC之间的努力。的 真菌病研究小组是独特的定位，以协调这些努力，因为他广泛的 设计、协调和实施临床和流行病学试验的历史， 自1978年以来，我们相信，在这个奖项完成后，我们将有移动 更接近于了解美国目前真菌感染的流行病学， 也将更清楚地了解那些处于特别高风险的人， 严重的并发症。此外，我们相信， 在改进现有真菌诊断的部署方面取得了重大进展， 在开发新的诊断方法方面取得进展。最后，我们将改善成果 通过提高公众认识和采取具体的战略干预措施， 风险最高的人和可能从预防策略中获得最大利益的人。

Project summary: This proposal which is entitled "Defining epidemiology, diagnosis, prevention and treatment of invasive fungal infections in the United States" is an ambitious and overarching proposal which covers a host of issues in the clinical mycology arena. This proposal represents a series of independent projects that will be initiated in sequential fashion throughout the course of this 5- year award. The Mycoses Study Group (MSG) with its central unit located at UAB in the division of infectious diseases will be administering this program. The proposal has 3 broad specific aims which address some of the most important current public health issues and challenges as it relates to fungal infections. In the first aim, we will develop and maintain reliable and innovative methods of national fungal surveillance while also assessing specific risk factors for acquiring these infections in the treatment and outcomes associated with these disorders. The second aim will address a huge gap in the management of invasive mycoses, specifically improving the utility and the scope of fungal diagnostics. We will explore this through reviewing the existing utilization of fungal diagnostics but also creating a specimen repository that is linked to specific patients with the purpose of developing new diagnostics. Finally, we will explore specific public health interventions which may serve to mitigate the significant impact of fungal infections both in the general population and in specific high-risk subgroups. To accomplish these ambitious goals obviously requires significant coordination of efforts among a broad range of investigators, clinical centers, laboratories, and the CDC. The Mycoses Study Group is uniquely positioned to coordinate these efforts given his extensive history of designing coordinating and implementing both clinical and epidemiologic trials in mycology since 1978. We believe that at the completion of this award we will have moved much closer to understanding of current epidemiology of fungal infections in the United States will also have a much clearer picture of those who are at particularly high risk of developing severe complications from these infections. Moreover, we believe that we will have made significant strides towards improved deployment of existing fungal diagnostics and significant progress towards the development of new diagnostics. Finally, we will improve outcomes through increased public awareness and specific and strategic interventions which target individuals at highest risk and who may realize the greatest benefit from preventative strategies.